2 completed. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
Follow PF-04523655: new trials by email Literature Review of PF-04523655 trials Research Report on PF-04523655
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME) PF-04523655 (Stratum I), ranibizumab, PF-04523655 (Stratum II) - Choroidal Neovascularization, Diabetic Retinopathy | Phase 2 | Completed | Quark Pharmaceuticals | 258 | 2012-02-01 | 2015-02-23 |
| Phase II Open Label Multicenter Study For Age Related Macular Degeneration Comparing PF-04523655 Versus Lucentis In The Treatment Of Subjects With CNV (MONET Study). 0.5 mg ranibizumab, 3 mg PF-04523655, 1 mg PF-04523655 - Age Related Macular Degeneration | Phase 2 | Completed | Quark Pharmaceuticals | 152 | 2009-11-01 | 2012-10-12 |
Choroidal Neovascularization (1) · Diabetic Retinopathy (1) · Macular Degeneration (1)
Israel (2) · United States (2) · Austria (1) · Belgium (1) · Czechia (1) · Denmark (1) · Germany (1) · Hong Kong (1) · India (1) · Philippines (1) · Poland (1) · South Korea (1) · Spain (1) · Taiwan (1) · Turkey (Türkiye) (1)
Rabia Ozden, MD (1)